Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Mar 09, 2021 11:52am
91 Views
Post# 32752851

RE:RE:Answer about the linker

RE:RE:Answer about the linkerAnother thing I learned in all my readings yesterday is that taxanes in general and docetaxel in particular is almost insoluble in water. The formulation for the drug contains 13% ethanol and polysorbate 80, an emulsifier. So another advantage of a PDC is to eliminate the need for dissolving agent for the drug since once chemically linked to the peptide, it's the overall solubility of the molecule that comes into play and the PDC molecule is soluble in water or saline. I read that these formulations for taxanes were contributing to side effects profile of taxanes.


Wino115 wrote: Really value-added research JFM!  I've had same question and I believe Spatrap mentioned this trial as a warning about getting too ahead of ourselves.  I did very (very) basic research thinking that science has moved on and learned.  That PDC v ADC primer that Scarlet put up a while back also mentioned some advances made on the linker and overall understanding of PDCs in the last few years. 

Obviously I don't have the ability to get to this level but the few things I found were that they have also found some sort of "oils" or something that can also coat the PDC and it sort of dissolves or something over an hour, giving the PDC time to travel to it's homing spot.  I have no idea if that is effective, real or what.  But know seeing what you've uncovered, it sounds like the actual structure is more evolved and specifically designed based on what was learned in the Zop failure.   Excellent and still worth a questino to Marsolais to understand this key issue better. 


<< Previous
Bullboard Posts
Next >>